Emerald Advisers LLC Raises Position in CVRx, Inc. (NASDAQ:CVRX)

Emerald Advisers LLC grew its holdings in shares of CVRx, Inc. (NASDAQ:CVRX - Free Report) by 47.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 593,898 shares of the company's stock after purchasing an additional 190,844 shares during the period. Emerald Advisers LLC owned approximately 2.45% of CVRx worth $7,525,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the stock. Bank of New York Mellon Corp grew its holdings in shares of CVRx by 4.5% in the fourth quarter. Bank of New York Mellon Corp now owns 30,377 shares of the company's stock worth $385,000 after acquiring an additional 1,296 shares during the period. Calamos Advisors LLC purchased a new position in CVRx during the fourth quarter valued at $134,000. Barclays PLC boosted its stake in CVRx by 312.5% during the third quarter. Barclays PLC now owns 19,067 shares of the company's stock valued at $169,000 after buying an additional 14,445 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of CVRx by 2.2% during the 3rd quarter. Geode Capital Management LLC now owns 295,124 shares of the company's stock valued at $2,600,000 after acquiring an additional 6,443 shares during the last quarter. Finally, XTX Topco Ltd bought a new stake in shares of CVRx in the 3rd quarter worth about $150,000. Hedge funds and other institutional investors own 75.27% of the company's stock.

CVRx Trading Down 2.1 %

Shares of CVRx stock traded down $0.27 during trading hours on Thursday, hitting $12.33. The company's stock had a trading volume of 153,074 shares, compared to its average volume of 285,689. The stock has a market cap of $321.02 million, a price-to-earnings ratio of -4.58 and a beta of 1.34. CVRx, Inc. has a twelve month low of $6.40 and a twelve month high of $19.24. The firm has a fifty day moving average of $14.13 and a 200-day moving average of $12.75. The company has a debt-to-equity ratio of 0.69, a quick ratio of 10.23 and a current ratio of 12.06.

Remove Ads

CVRx (NASDAQ:CVRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 4th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.06). CVRx had a negative net margin of 116.91% and a negative return on equity of 93.06%. Research analysts forecast that CVRx, Inc. will post -1.91 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on CVRX shares. William Blair raised CVRx from a "market perform" rating to an "outperform" rating in a research note on Tuesday, January 14th. Canaccord Genuity Group lifted their price objective on shares of CVRx from $22.00 to $23.00 and gave the stock a "buy" rating in a research report on Wednesday, February 5th. Craig Hallum raised their price target on CVRx from $20.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Finally, Piper Sandler upped their target price on CVRx from $16.00 to $20.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat, CVRx has an average rating of "Moderate Buy" and a consensus price target of $17.83.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.